[Efficiency and safety of peptide receptor radionuclide therapy in the treatment of metastatic neuroendocrine tumors].
Zhonghua Yi Xue Za Zhi
; 102(14): 1034-1038, 2022 Apr 12.
Article
en Zh
| MEDLINE
| ID: mdl-35399024
ABSTRACT
The clinical data of 14 patients with neuroendocrine tumors who received Peptide Receptor Radionuclide Therapy (PRRT) from December 2018 to May 2021 were retrospectively analyzed. Among them, 2 patients demonstrated proprogressive disease, 2 patients had partial response, and 10 patients had stable disease. Grade 1-2 myelosuppression occurred in 5 patients. and 1 patient became grade 3 myelosuppressionï¼which recovered to grade 2 after symptomatic treatment. No grade 2 or higher treatment-related renal toxicity was observed in any of the patients. PRRT is efficacy and no significant side effects for unresectable metastatic neuroendocrine tumors.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tumores Neuroendocrinos
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
Zh
Revista:
Zhonghua Yi Xue Za Zhi
Año:
2022
Tipo del documento:
Article
País de afiliación:
China